JP2011246449A - Ophthalmic composition for soft contact lens - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an ophthalmic composition for soft contact lenses capable of suppressing adsorption on a soft contact lens, of an antihistamine selected especially from chlorpheniramine, diphenhydramine or salts thereof.SOLUTION: This ophthalmic composition for soft contact lenses includes (A) an antihistamine, (B) glycyrrhizic acid and/or its salt, (C) chondroitin sulfate and/or its salt, and (D) ≥0.5 w/v% polyvinylpyrrolidone, and has pH of 5.5-6.8.

Description

  The present invention particularly relates to an ophthalmic composition for a soft contact lens containing an antihistamine selected from chlorpheniramine, diphenhydramine and salts thereof, an adsorption inhibitor for the soft contact lens of the above antihistamine, and an adsorption suppression method.

  When a soft contact lens (SCL) is mounted, the lens surface is dried and pollen and contaminants from the outside are likely to adhere, and allergic symptoms such as itching and inflammatory hyperemia are likely to occur. Therefore, a soft contact lens user composition containing an anti-inflammatory component, an antihistamine component or an anti-hyperemia component has been desired for some time.

  Among them, diphenhydramine, chlorpheniramine and salts thereof, which are antihistamine components, are excellent in the effect of suppressing itching and are widely used in eye drops for the purpose of suppressing itching. However, these antihistamine components have a high affinity with soft contact lenses, so when used as a composition for soft contact lens users, they can be adsorbed on the lens surface and accumulate in the lens over time. There is a possibility of adverse effects such as physical properties of the lens, feeling during use, and side effects. Therefore, in order to adapt to the soft contact lens user, it is necessary to suppress the adsorption of the antihistamine component to the lens.

  Conventionally, as a method of suppressing the adsorption of a drug to a soft contact lens, a method of suppressing the adsorption of a fat-soluble vitamin with a polymer compound and a nonionic surfactant (see Patent Document 1: JP 2001-158734 A), A method for suppressing adsorption of dipotassium glycyrrhizinate with an amino acid or the like (Patent Document 2: Japanese Patent Application Laid-Open No. 2001-002563), a method for suppressing protein adsorption with hydroxypropylmethylcellulose (Patent Document 3: Japanese Patent Application Laid-Open No. 2002-322048) Patent Literature 4), and a method for suppressing adsorption of a cooling agent with polyhydric alcohols (see Patent Literature 4: Japanese Patent Laid-Open No. 2001-122774). In addition, a method for suppressing adsorption of chlorpheniramine maleate to a container by adjusting the pH of the composition to 5 to 6 (see Patent Document 5: JP 2002-249445 A), a cyclodextrin, and a container There is known a method for suppressing the adsorption to the surface (see Patent Document 6: Japanese Patent Application Laid-Open No. 2004-359679). Moreover, as a method for suppressing the adsorption of the antihistamine component to the soft contact lens, the pH of the composition is adjusted to 3.5 to 4.8, whereby the basic drug containing the antihistamine component is applied to the soft contact lens. Methods of suppressing adsorption (Patent Document 7: JP 2009-161455 A, Patent Document 8: International Publication No. 2007/077783 pamphlet) are known, but adsorption to a soft contact lens in a neutral region is suppressed. The method is not known.

JP 2001-158734 A JP 2001-002563 A JP 2002-322048 A JP 2001-122774 A JP 2002-249445 A JP 2004-359679 A JP 2009-161455 A International Publication No. 2007/077783 Pamphlet

  The present invention has been made in view of the above circumstances, and in particular, to provide an ophthalmic composition for a soft contact lens that suppresses the adsorption of an antihistamine selected from chlorpheniramine, diphenhydramine, and salts thereof to the soft contact lens. Objective. Another object of the present invention is to provide an adsorption inhibitor and a method for inhibiting adsorption of the antihistamine to the soft contact lens.

  As a result of intensive studies to achieve the above object, the inventors of the present invention have developed glycyrrhizic acid and / or a salt thereof into an ophthalmic composition for soft contact lenses containing an antihistamine selected from chlorpheniramine, diphenhydramine, and salts thereof. And chondroitin sulfate and / or a salt thereof and a polyvinyl pyrrolidone of 0.5 w / v% (mass / volume% (g / 100 mL), the same applies hereinafter) or more in combination, and the pH of this composition is 5. Surprisingly, the effect of suppressing the adsorption of the antihistamine to the soft contact lens, which is not achieved when these are used alone or in combination of two, can be obtained by adjusting to 5 to 6.8. The headline and the present invention were made.

Accordingly, the present invention provides the following ophthalmic composition for soft contact lenses, an antihistamine adsorption inhibitor and a method for inhibiting adsorption to soft contact lenses.
Claim 1:
(A) an antihistamine, (B) glycyrrhizic acid and / or a salt thereof, (C) chondroitin sulfate and / or a salt thereof, and (D) polyvinyl pyrrolidone of 0.5 w / v% or more, and having a pH of 5 An ophthalmic composition for soft contact lenses, characterized in that it is .5 to 6.8.
Claim 2:
The ophthalmic composition for soft contact lenses according to claim 1, wherein the antihistamine as the component (A) is at least one selected from chlorpheniramine and a salt thereof and diphenhydramine and a salt thereof.
Claim 3:
The ophthalmic composition for soft contact lenses according to claim 1 or 2, further comprising (E) a nonionic surfactant.
Claim 4:
The ophthalmic composition for a soft contact lens according to any one of claims 1 to 3, wherein the soft contact lens is a group IV lens according to FDA contact lens classification.
Claim 5:
The ophthalmic composition for soft contact lenses according to any one of claims 1 to 4, wherein the composition does not contain a preservative.
Claim 6:
The soft contact lens according to any one of claims 1 to 5, further comprising (F) one or more components selected from boric acid, borate, trometamol, sodium edetate, menthol, camphor, borneol and geraniol. Ophthalmic composition.
Claim 7:
(A) an anti-histamine agent, an adsorption inhibitor blended in an ophthalmic composition for soft contact lenses having a pH of 5.5 to 6.8, wherein (B) glycyrrhizic acid and / or a salt thereof; C) Chondroitin sulfate and / or a salt thereof, and (D) polyvinylpyrrolidone, wherein the content of the component (D) in the composition is blended so as to be 0.5 w / v% or more. An adsorption inhibitor for the soft contact lens of the component (A).
Claim 8:
(A) An ophthalmic composition for soft contact lenses containing an antihistamine, (B) glycyrrhizic acid and / or a salt thereof, (C) chondroitin sulfate and / or a salt thereof, and (D) 0.5 w / v% or more A method for suppressing adsorption of the component (A) to the soft contact lens, which comprises blending the polyvinylpyrrolidone with a pH of 5.5 to 6.8.

  ADVANTAGE OF THE INVENTION According to this invention, the ophthalmic composition for soft contact lenses which suppressed adsorption | suction to the soft contact lens of the antihistamine selected from chlorpheniramine, diphenhydramine, and these salts can be provided. Moreover, according to this invention, the antihistamine adsorption inhibitor and the adsorption | suction suppression method to a soft contact lens can be provided.

<(A) Antihistamine>
The antihistamine agent (A) is an active ingredient of the present invention, and includes chlorpheniramine, diphenhydramine, and salts thereof. More specifically, chlorpheniramine maleate and diphenhydramine hydrochloride are preferable. These can be used individually by 1 type or in combination of 2 or more types.
In the case of chlorpheniramine or a salt thereof, the blending amount of these components is preferably 0.001 to 1.0 w / v%, more preferably 0.001 to 0.3 w / v in the ophthalmic composition for soft contact lenses. v%, more preferably in the range of 0.005 to 0.03 w / v%. If it is less than 0.001 w / v%, the antihistamine action may be insufficient, and if it exceeds 1.0 w / v%, an improvement in the effect may not be expected. If it is the range of 0.001-1.0 w / v%, a favorable effect will be acquired from the point of effectiveness.
In the case of diphenhydramine or a salt thereof, 0.001 to 1.0 w / v% is preferable in the ophthalmic composition for soft contact lenses, more preferably 0.005 to 0.5 w / v%, and still more preferably 0. The range is from 0.01 to 0.05 w / v%. If it is less than 0.001 w / v%, the antihistamine action may be insufficient, and if it exceeds 1.0 w / v%, an improvement in the effect may not be expected. If it is the range of 0.001-1.0 w / v%, a favorable effect will be acquired from the point of effectiveness.

<(B) Glycyrrhizic acid and its salt>
Glycyrrhizic acid and its salt are anti-inflammatory agents, and when added to an ophthalmic composition containing the component (A), the component (A) is suppressed from adsorbing to the soft contact lens. Examples of glycyrrhizic acid and salts thereof include glycyrrhizic acid salts such as dipotassium glycyrrhizinate in addition to glycyrrhizic acid itself. These can be used individually by 1 type or in combination of 2 or more types. Glycyrrhizic acid and / or a salt thereof can be usually mixed in an ophthalmic composition in an amount of 0.01 to 3.0 w / v%, preferably 0.01 to 1.0 w / v%, more preferably 0. 0.05 to 0.5 w / v%, and more preferably 0.06 to 0.25 w / v%. If it is the range of 0.01-3.0 w / v%, a favorable effect will be acquired from the point of an anti-inflammatory effect and adsorption | suction suppression.

<(C) Chondroitin sulfate and its salt>
Chondroitin sulfate and a salt thereof are a kind of amino acid, and by adding to an ophthalmic composition containing the component (A), the component (A) is suppressed from adsorbing to the soft contact lens. In addition to chondroitin sulfate itself, chondroitin sulfate and salts thereof include chondroitin sulfate salts such as sodium chondroitin sulfate. These can be used individually by 1 type or in combination of 2 or more types. Chondroitin sulfate and / or a salt thereof can be usually mixed in an ophthalmic composition in an amount of 0.01 to 5.0 w / v%, preferably 0.01 to 3.0 w / v%, more preferably 0. The range is from 0.05 to 1.0 w / v%, more preferably from 0.1 to 0.5 w / v%. If it is the range of 0.01-5.0 w / v%, the effect favorable from the point of the effect of this invention and the usability | use_condition of an ophthalmic composition will be acquired.

<(D) Polyvinylpyrrolidone>
Polyvinyl pyrrolidone is a kind of thickening agent, and by further adding to the components (B) and (C), the adsorption suppressing effect of the component (A) on the soft contact lens can be remarkably enhanced, and the feeling of use is also improved. To do. The weight average molecular weight of polyvinyl pyrrolidone is not particularly limited, and is preferably 1,000 to 1,500,000, more preferably 10,000 to 1,500,000. In the present invention, the weight average molecular weight is a value measured by a light scattering method. Examples of polyvinylpyrrolidone include Kollidon (12PF, 17PF, 25, 30, 90F) manufactured by BASF Japan. These can be used individually by 1 type or in combination of 2 or more types. The content of polyvinylpyrrolidone is 0.5 w / v% or more with respect to the total amount of the ophthalmic composition, preferably 0.5 to 20 w / v%, more preferably 0.5 to 15 w / v%, More preferably, it is 0.5-10 w / v%. If it is in the said range, a favorable effect will be acquired in the point of adsorption | suction suppression and a feeling of use.

<(E) Nonionic surfactant>
In the present invention, the addition of (E) nonionic surfactant to the components (B) to (D) further suppresses the adsorption of the component (A) to the soft contact lens. Examples of the nonionic surfactant include higher fatty acid esters such as water-soluble polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan higher fatty acid ester, sucrose fatty acid ester, polyoxyethylene polyoxypropylene glycol, and the like. Specifically, for example, polyoxyethylene (p = 40, 50, 60) hydrogenated castor oil, polyoxyethylene (p = 20) sorbitan monooleate (polysorbate 80), polyoxyethylene (200) polyoxypropylene (70 ) Glycol and the like. More specifically, for example, polyoxyethylene hydrogenated castor oil such as HCO-40, HCO-50, HCO-60 (polyoxyethylene hydrogenated castor oil 60) manufactured by Nikko Chemicals Co., Ltd., polyoxyethylene sorbitan monooleate As examples, polyoxyethylene polyoxypropylene glycol such as TO-10MV manufactured by Nikko Chemicals Co., Ltd., Lutrol F127 manufactured by BASF Japan Co., Ltd., Unilube 70DP-950B manufactured by NOF Corporation, and the like can be given. These can be used individually by 1 type or in combination of 2 or more types. Among these, polyoxyethylene (p = 60) hydrogenated castor oil, polyoxyethylene (p = 20) sorbitan monooleate, polyoxyethylene (200) polyoxypropylene (70) glycol and the like are preferably used. (E) Although the compounding quantity of a component is not restrict | limited in particular, Usually, 0.001-10.0 w / v% is preferable with respect to the whole composition, More preferably, it is 0.01-5.0 w / v%. More preferably, it is the range of 0.05-3.0 w / v%. If it is the range of 0.001-10.0 w / v%, a preferable effect will be acquired from the point of the effect of this invention and the property of an ophthalmic composition. In the case of a cationic surfactant, the effect of the present invention is not sufficient, and since the cationic surfactant itself is adsorbed to the soft contact lens, it is preferably not used in the present invention from the viewpoint of reducing irritation. .

<Other ingredients>
In the ophthalmic composition of the present invention, in addition to the above components, various components that can be blended in the ophthalmic composition can be blended within a range not impairing the effects of the present invention. These components include buffers, thickeners, pH adjusters, preservatives, isotonic agents, stabilizers, cooling agents, drugs, water and the like. These can be used individually by 1 type or in combination of 2 or more types, respectively, and can mix | blend suitable amount.

  Examples of the buffer include boric acid or a salt thereof (such as borax), citric acid or a salt thereof (such as sodium citrate), phosphoric acid or a salt thereof (such as sodium monohydrogen phosphate), tartaric acid or a salt thereof (tartaric acid) Sodium), gluconic acid or a salt thereof (sodium gluconate, etc.), acetic acid or a salt thereof (sodium acetate, etc.), various amino acids (ε-aminocaproic acid, potassium aspartate, aminoethylsulfonic acid, glutamic acid, sodium glutamate, etc.) And trometamol. Of these, trometamol is preferable from the viewpoint of the effect of mitigating the irritation caused by drugs such as an antihistamine and the antiseptic effect. Further, when boric acid and borax are used in combination, a particularly high antiseptic effect is obtained. The content of the buffer is preferably 0.001 to 10 w / v% in the ophthalmic composition, and more preferably 0.01 to 5 w / v%.

  Examples of the thickener include hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, polyvinyl alcohol, sodium hyaluronate, polyacrylic acid, carboxyvinyl polymer, and the like. The blending amount of the thickening agent is, for example, preferably 0.001 to 10 w / v% in the ophthalmic composition, more preferably 0.001 to 5 w / v%, still more preferably 0.01 to 3 w / v%. is there.

  As the pH adjuster, it is preferable to use an inorganic acid or an inorganic alkali agent. For example, (dilute) hydrochloric acid etc. are mentioned as an inorganic acid. Examples of the inorganic alkaline agent include sodium hydroxide, potassium hydroxide, sodium carbonate, sodium hydrogen carbonate and the like. Of these, hydrochloric acid and sodium hydroxide are preferable. The blending amount of the pH adjusting agent is, for example, preferably 0.00001 to 10 w / v% in the ophthalmic composition, more preferably 0.0001 to 5 w / v%, still more preferably 0.001 to 3 w / v%. .

  Examples of the preservative include quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride, polydronium chloride, polyhexamethylene biguanide, sorbic acid or a salt thereof, paraoxybenzoic acid ester (methylparaben, ethylparaben, propylparaben, etc.) And phenylethyl alcohol. The preservative content is, for example, preferably 0.00001 to 5 w / v% in the ophthalmic composition, more preferably 0.0001 to 3 w / v%, and still more preferably 0.001 to 2 w / v%. In addition, it does not contain the above-mentioned preservative (compound), is filled into a container with a sterile filter, a unit dose-type container or a single-use container, or is replaced with the above-mentioned preservative compound, the above-mentioned buffer or One or more selected from (F) boric acid, borate (borax), trometamol, sodium edetate, menthol, camphor, borneol and geraniol, preferably listed as the following cooling agents An antiseptic effect can also be exhibited by a composition in which two or more are appropriately combined. In particular, a composition (preservative composition) that is a combination of boric acid, trometamol, and sodium edetate is preferably used, and it is a combination of one or more selected from menthol, camphor, borneol, and geraniol. It is more preferable to improve the antiseptic power of the. It is most preferable from the viewpoint of reducing eye irritation that an ophthalmic solution using the above preservative composition is filled in a multi-dose normal container.

  Examples of the isotonic agent include sodium chloride and potassium chloride. The blending amount of the isotonic agent is, for example, preferably 0.001 to 5 w / v% in the ophthalmic composition, more preferably 0.01 to 3 w / v%, still more preferably 0.1 to 2 w / v%. is there.

  Examples of the stabilizer include sodium edetate hydrate, cyclodextrin, sulfite, dibutylhydroxytoluene and the like. The blending amount of the stabilizer is, for example, preferably 0.001 to 5 w / v% in the ophthalmic composition, more preferably 0.01 to 3 w / v%, still more preferably 0.1 to 2 w / v%. . Among these, sodium edetate is preferable for enhancing the antiseptic power and enhancing the stability of the drug.

  Examples of the refreshing agent include menthol, camphor, borneol, geraniol, and the like. The content of the refreshing agent is preferably 0.0001 to 5 w / v%, more preferably 0.001 to 2 w / v%, and more preferably 0.005 to 1 w / v%, as the total amount of the compound in the ophthalmic composition. Further preferred is 0.007 to 0.8 w / v%.

  Examples of drugs (pharmaceutical active ingredients) include other antihistamines (for example, iproheptin hydrochloride, isothipentyl hydrochloride, etc.), vitamins (for example, retinol acetate, retinol palmitate, pyridoxine hydrochloride, pantenol, calcium pantothenate, pantothenic acid) Sodium, tocopherol acetate, flavin adenine dinucleotide, cyanocobalamin), decongestant (eg, naphazoline hydrochloride, tetrahydrozoline hydrochloride, phenylephrine hydrochloride, epinephrine, ephedrine hydrochloride, dl-methylephedrine hydrochloride, tetrahydrozoline nitrate, naphazoline nitrate), anti-inflammation / convergence Agents (for example, neostigmine methyl sulfate, ε-aminocaproic acid, allantoin, berberine chloride, zinc sulfate, zinc lactate, lysozyme chloride, methyl salicylate) Tranexamic acid, sodium azulenesulfonate, etc.), amino acids (eg, potassium L-aspartate, magnesium L-aspartate, aminoethylsulfonic acid, etc.), sulfa drugs, fungicides (eg, sulfur, isopropylmethylphenol, hinokitiol, etc.), A local anesthetic (eg, lidocaine, lidocaine hydrochloride, procaine hydrochloride, dibucaine hydrochloride, etc.) and an antiallergic agent (eg, ketotifen fumarate, etc.) can be appropriately blended.

  The amount of these components in the ophthalmic composition is appropriately selected according to the type of preparation, the type of drug, etc., and the amounts of various components are known in the technical field to which the present invention belongs. For example, 0.0001-30 w / v% is preferable with respect to the whole ophthalmic composition, More preferably, it can select from the range of about 0.001-10 w / v%. More specifically, the content of each component is, for example, as follows for the ophthalmic composition.

  If it is an antihistamine, it is 0.0001-10 w / v%, for example, Preferably it is 0.001-5 w / v%. If it is a vitamin, it is 0.0001-1 w / v%, Preferably it is 0.0001-0.5 w / v%. If it is a decongestant, for example, it is 0.0001 to 0.5 w / v%, preferably 0.0005 to 0.3 w / v%, more preferably 0.001 to 0.1 w / v%. If it is a flame retardant / astringent, it is 0.0001-10 w / v%, for example, Preferably it is 0.0001-5 w / v%. If it is an amino acid, it is 0.0001-10 w / v%, Preferably it is 0.001-3 w / v%. If it is a sulfa agent and a disinfectant, it is 0.00001-10 w / v%, for example, Preferably it is 0.0001-10 w / v%. If it is a local anesthetic, it is 0.001-1 w / v%, for example, Preferably it is 0.01-1 w / v%. If it is an antiallergic agent, it is 0.001-5 w / v%, for example, Preferably it is 0.01-3 w / v%.

<PH 5.5 to 6.8>
The ophthalmic composition of the present invention has a pH (20 ° C.) of 5.5 to 6.8, preferably 5.8 to 6.5, more preferably 5.8 to 6.4. If the pH is too high, the adsorption suppression effect is reduced. By adjusting the pH of the composition so as to be in this range, a favorable effect can be obtained in terms of the effect of the present invention and the feeling of use of the ophthalmic composition. In the present invention, the pH value is a value measured at 20 ° C. using a pH osmometer (HOSM-1, manufactured by Toa DKK Corporation).

<Viscosity>
The ophthalmic composition of the present invention is liquid, and the viscosity of the ophthalmic composition is preferably 1 to 50 mPa · s, more preferably 1 to 20 mPa · s, and still more preferably 1 to 15 mPa · s. In the present invention, the viscosity is measured at 20 ° C. using an E-type viscometer (VISCONIC ELD-R, manufactured by Tokyo Keiki Co., Ltd.).

<Manufacturing method>
The preparation method of the ophthalmic composition of the present invention is not particularly limited. For example, the components (A) to (D) and, if necessary, the component (E) in an aqueous solvent such as purified water. And other components can be obtained by adjusting the pH by adding predetermined concentrations. Thereafter, it can be aseptically filled into a suitable container such as a container made of polyethylene terephthalate.

  Specific examples of usage forms of the ophthalmic composition of the present invention include eye drops for soft contact lenses, soft contact lens mounting liquid, soft contact lens removal liquid, and the like. The type of soft contact lens to which the ophthalmic composition for soft contact lens of the present invention can be applied is not particularly limited, and is a one-day disposable soft contact lens, a one-week disposable soft contact lens, a two-week disposable soft contact lens. It can be used for either of these. In particular, among the soft contact lens classification groups I to IV according to the US Food and Drug Administration (FDA) standard, the soft contact lens of group IV (high water content (50% by mass or more) and ionic) in which (A) component is easily adsorbed A higher antihistamine adsorption suppression effect can be obtained. The group IV soft contact lens has a negative charge due to containing methacrylic acid, and is considered to be adsorbed by the electrostatic interaction with the component (A) having a positive charge in the solution. It is done.

  Since the ophthalmic composition for soft contact lenses of the present invention has an effect of suppressing adsorption of antihistamines such as component (A) chlorpheniramine, diphenhydramine and salts thereof to soft contact lenses, the antihistamine soft contact lenses described above It is suitable as an adsorption inhibitor. Although the mechanism is not clear, each of the components (B) to (D) is an anionic component having a negative charge, and by interacting with the positive charge of the component (A), the adsorption suppressing effect is exerted. It is thought that it demonstrates.

Furthermore, the present invention provides the following adsorption inhibitor and adsorption suppression method. Suitable components, blending amounts, and the like are the same as those for the ophthalmic composition.
(A) an anti-histamine agent, an adsorption inhibitor blended in an ophthalmic composition for soft contact lenses having a pH of 5.5 to 6.8, wherein (B) glycyrrhizic acid and / or a salt thereof; C) Chondroitin sulfate and / or a salt thereof, and (D) polyvinylpyrrolidone, wherein the content of the component (D) in the composition is blended so as to be 0.5 w / v% or more. An adsorption inhibitor for the soft contact lens of the component (A).
(A) An ophthalmic composition for soft contact lenses containing an antihistamine, (B) glycyrrhizic acid and / or a salt thereof, (C) chondroitin sulfate and / or a salt thereof, and (D) 0.5 w / v% or more A method for suppressing adsorption of the component (A) to the soft contact lens, which comprises blending the polyvinylpyrrolidone with a pH of 5.5 to 6.8.

  EXAMPLES Hereinafter, although an Example and a comparative example are shown and this invention is demonstrated more concretely, this invention is not restrict | limited to the following Example.

[Examples 1 to 17, Comparative Examples 1 to 10]
After dissolving each compounding component in the table in sterilized purified water according to a conventional method so as to have the composition shown in Tables 1 to 3 (compounding unit: w / v%), each solution is aseptically filtered and soft contacted. A lens ophthalmic composition was prepared. The following test was implemented about each obtained composition. The results are shown in Tables 1 and 2.

[Test 1: Adhesion evaluation test of antihistamine to soft contact lens]
(Adsorption evaluation test of antihistamine on soft contact lens: n = 3)
5 mL of each ophthalmic composition for soft contact lenses was dispensed into 20 mL vials, and one soft contact lens was immersed in each vial. After the vial in which the lens was immersed was shaken and stirred at 37 ° C. for 7 days, the amount of antihistamine in the solution was quantified by liquid chromatography according to a conventional method and by comparison with a standard sample. Using the same treatment without immersing the lens as a control, the lens adsorption rate (%) of the antihistamine to the soft contact lens was calculated from the ratio to the amount of the antihistamine in the control solution based on the following formula. Measurement was performed three times for one type of ophthalmic composition for soft contact lenses, and after calculating the average adsorption rate for the lens, evaluation was performed based on the following evaluation criteria.

(Lens adsorption rate calculation formula)
Lens adsorption rate (%) = [(control antihistamine amount−controlling antihistamine amount) / control antihistamine amount] × 100
(Soft contact lens used)
Soft contact lenses are classified into FDA (US Food and Drug Administration) 4 groups (Groups I-IV). Group IV lenses (high water content and ionic lenses) are most easily adsorbed by chlorpheniramine maleate and diphenhydramine hydrochloride. ) Was used. Specifically, Accuview (manufactured by Johnson & Johnson Medical Co., Ltd.) was used.
(Evaluation criteria for adsorption suppression effect for soft contact lenses)
A: The average adsorption rate of the antihistamine to the lens is less than 5%. O: The average adsorption rate of the antihistamine to the lens is from 5% to less than 7%. Δ: The average adsorption rate of the antihistamine to the lens is from 7% to less than 10% X: The antihistamine to the lens Average adsorption rate of 10% or more

ポリビニルピロリドン（ＰＶＰ Ｋ２５）：商品名「Ｋｏｌｌｉｄｏｎ ２５」、ＢＡＳＦジャパン（株）製

Polyvinylpyrrolidone (PVP K25): Trade name “Kollidon 25”, manufactured by BASF Japan Ltd.

  As shown in the results of Examples 1 to 7 and Comparative Examples 1 to 10, chlorpheniramine is obtained by using dipotassium glycyrrhizinate, sodium chondroitin sulfate and a specific amount of polyvinylpyrrolidone in combination and bringing the pH within a predetermined range. The adsorption suppression effect of maleate and diphenhydramine hydrochloride on soft contact lenses could be dramatically improved.

Polyvinylpyrrolidone (PVP K25): Trade name “Kollidon 25”, BASF Japan KK polyvinyl pyrrolidone (PVP K30): Trade name “Kollidon 30”, BASF Japan KK polyvinyl pyrrolidone (PVP K90): Trade name “ Kollidon 90F ", BASF Japan Co., Ltd. polysorbate 80: trade name" NIKKOL TO-10MV ", Nikko Chemicals Co., Ltd. polyoxyethylene hydrogenated castor oil 60: trade names" NIKKOL HCO-60 ", Nikko Chemicals Corporation Polyoxyethylene (200) Polyoxypropylene (70) Glycol: Trade name “Unilube 70DP-950B”, manufactured by NOF Corporation

[Examples 18 to 21]
Further, after dissolving each compounding component in the table in sterilized purified water according to a conventional method so as to have the composition shown in Table 4 (compounding unit: w / v%), each solution is subjected to aseptic filtration and soft contact. A lens ophthalmic composition was prepared. About each obtained composition, in addition to the said test, the following test was implemented. The results are also shown in the table.

[Irritation]
10 expert panelists sensitive to irritability instilled 2 drops (80-100 μL) of an ophthalmic composition filled in a multi-dose type eye drop container, and the following evaluation criteria It was evaluated by. A result is shown based on the following irritation | stimulation evaluation from the average score of evaluation.
(Evaluation criteria)
5: Not at all 4: Slightly visible 3: Slightly visible 2: Stained 1: Slightly visible

(Irritation evaluation)
◎: Average score is 4.5 or more ○: Average score is 4.0 or more and less than 4.5 Δ: Average score is 3.0 or more and less than 4.0 ×: Average score is less than 3.0

[Preservation power]
When the test is conducted based on the preservative efficacy test described in the Japanese Pharmacopoeia Reference Information ("Fifteenth Amendment Japanese Pharmacopoeia Explanation Reference Information 28. Preservative Power Testing Method"), "If not satisfied," x ".

  As shown in Table 4, the ophthalmic composition for soft contact lens of the present invention had no eye irritation and had sufficient antiseptic power as an eye drop.

[Examples 22 to 33]
Each composition component in the table is dissolved in sterilized purified water according to a conventional method so that the composition shown in Tables 5 and 6 (composition unit: w / v%) is obtained. A lens ophthalmic composition was prepared.

Claims (8)

  (A) an antihistamine, (B) glycyrrhizic acid and / or a salt thereof, (C) chondroitin sulfate and / or a salt thereof, and (D) polyvinyl pyrrolidone of 0.5 w / v% or more, and having a pH of 5 An ophthalmic composition for soft contact lenses, characterized in that it is .5 to 6.8.   The ophthalmic composition for soft contact lenses according to claim 1, wherein the antihistamine as the component (A) is at least one selected from chlorpheniramine and a salt thereof and diphenhydramine and a salt thereof.   The ophthalmic composition for soft contact lenses according to claim 1 or 2, further comprising (E) a nonionic surfactant.   The ophthalmic composition for a soft contact lens according to any one of claims 1 to 3, wherein the soft contact lens is a group IV lens according to FDA contact lens classification.   The ophthalmic composition for soft contact lenses according to any one of claims 1 to 4, wherein the composition does not contain a preservative.   The soft contact lens according to any one of claims 1 to 5, further comprising (F) one or more components selected from boric acid, borate, trometamol, sodium edetate, menthol, camphor, borneol and geraniol. Ophthalmic composition.   (A) an anti-histamine agent, an adsorption inhibitor blended in an ophthalmic composition for soft contact lenses having a pH of 5.5 to 6.8, wherein (B) glycyrrhizic acid and / or a salt thereof; C) Chondroitin sulfate and / or a salt thereof, and (D) polyvinylpyrrolidone, wherein the content of the component (D) in the composition is blended so as to be 0.5 w / v% or more. An adsorption inhibitor for the soft contact lens of the component (A).   (A) An ophthalmic composition for soft contact lenses containing an antihistamine, (B) glycyrrhizic acid and / or a salt thereof, (C) chondroitin sulfate and / or a salt thereof, and (D) 0.5 w / v% or more A method for suppressing adsorption of the component (A) to the soft contact lens, which comprises blending the polyvinylpyrrolidone with a pH of 5.5 to 6.8.